IRON analyst estimates
Disc Medicine (IRON) analyst ratings, the average price target and its range, and every firm's latest call.
IRON analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 21, 2026 | Jefferies | Disc Medicine (IRON) PT Raised to $149 at Jefferies | $149.00 |
| Oct 20, 2026 | Wells Fargo | Disc Medicine (IRON) PT Raised to $124 at Wells Fargo | $124.00 |
| Oct 20, 2026 | Cantor Fitzgerald | Disc Medicine (IRON) PT Raised to $170 at Cantor Fitzgerald on Ph3 Results for Bitopertin | $170.00 |
| Oct 20, 2026 | Morgan Stanley | Disc Medicine price target raised to $92 from $90 at Morgan Stanley | $92.00 |
| Oct 19, 2026 | BMO Capital | Disc Medicine price target raised to $120 from $100 at BMO Capital | $120.00 |
| Oct 19, 2026 | Truist Financial | Disc Medicine price target raised to $115 from $83 at Truist | $115.00 |
| Sep 16, 2026 | Wells Fargo | Disc Medicine price target raised to $86 from $79 at Wells Fargo | $86.00 |
| Sep 10, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Disc Medicine (IRON) | $128.00 |
| Sep 10, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON) | $120.00 |
| Aug 17, 2026 | Morgan Stanley | Disc Medicine price target raised to $90 from $85 at Morgan Stanley | $90.00 |
| Jun 15, 2026 | Morgan Stanley | Disc Medicine price target raised to $85 from $80 at Morgan Stanley | $85.00 |
| May 14, 2026 | Morgan Stanley | Disc Medicine price target raised to $80 from $75 at Morgan Stanley | $80.00 |
| Feb 17, 2026 | Morgan Stanley | Disc Medicine price target lowered to $75 from $120 at Morgan Stanley | $75.00 |
| Feb 17, 2026 | Cantor Fitzgerald | Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald | $125.00 |
| Feb 17, 2026 | Wedbush | Disc Medicine price target lowered to $88 from $110 at Wedbush | $88.00 |
- 8 firms rate IRON: 8 buy, 0 hold, 0 sell.
- The average price target is $127.14 from 7 analysts, from $92.00 to $170.00.
Updated 2026-11-07 11:52 UTC